Literature DB >> 15235586

Overexpression of the thymosin beta-4 gene is associated with increased invasion of SW480 colon carcinoma cells and the distant metastasis of human colorectal carcinoma.

Wei-Shu Wang1, Po-Min Chen, Hung-Liang Hsiao, Huann-Sheng Wang, Wen-Yih Liang, Yeu Su.   

Abstract

Cell-matrix and cell-cell adhesive interactions play important roles in the normal organization and stabilization of the cell layer in epithelial tissue. Alterations in the expression and function of these adhesion systems that cause a switch to a migratory phenotype in tumor invasion and metastasis are critical for the malignant conversion of epithelial cells. Thymosin beta-4 (Tbeta-4) is the major actin-sequestering protein that has been shown to be upregulated in a wide variety of human carcinomas and has been implicated to be involved in altering the motility of certain tumors. We have recently demonstrated that the growth rate, colony formation in soft agar, and motility, all good indicators for malignant progression, of SW480 colon carcinoma cells are dramatically increased by enforced Tbeta-4 expression. To test the hypothesis that overexpression of this G-actin sequestering peptide also promotes tumor invasion, we examined not only the invasion capability of Tbeta-4-overexpressing SW480 cells, but also the expression levels of Tbeta-4 as well as several proteins that participate in different stages of tumor progression in matched samples of human primary colorectal adenocarcinoma and liver metastases from several patients. A marked increase on the invasiveness in Tbeta-4-overexpressing SW480 cells with increased levels and activity of matrix metalloproteinase-7 (MMP-7) was observed. Furthermore, the levels of Fas as well as the susceptibility to Fas ligand-mediated apoptosis in Tbeta-4-overexpressing cells were significantly decreased. Interestingly, the levels of Tbeta-4 mRNA, beta-catenin, c-Myc, and MMP-7 in metastatic liver lesions were relatively higher, whereas the levels of E-cadherin and Fas were significantly lower than those in the matched primary colorectal tumors. These results suggest that upregulation of Tbeta-4, by promoting the disruption of cell-cell adhesion and a consequential activation of the beta-catenin signaling, could be a key event in the acquisition of growth advantages as well as invasive phenotypes in human colorectal carcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15235586     DOI: 10.1038/sj.onc.1207888

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  37 in total

1.  In vivo growth suppression of CT-26 mouse colorectal cancer cells by adenovirus-expressed small hairpin RNA specifically targeting thymosin beta-4 mRNA.

Authors:  T-C Chao; L-C Chan; S-Y Ju; M-C Tang; C-Y Liu; P-M Chen; C-H Tzeng; Y Su
Journal:  Cancer Gene Ther       Date:  2014-08-15       Impact factor: 5.987

2.  Shear force-based genetic screen reveals negative regulators of cell adhesion and protrusive activity.

Authors:  Thomas J Lampert; Nadine Kamprad; Marc Edwards; Jane Borleis; Ayende J Watson; Marco Tarantola; Peter N Devreotes
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-28       Impact factor: 11.205

3.  Molecular cloning and structural characterization of the functional human thymosin beta4 gene.

Authors:  Shu-Ping Yang; Hui-Ju Lee; Yeu Su
Journal:  Mol Cell Biochem       Date:  2005-04       Impact factor: 3.396

4.  Expression patterns of Thymosin β4 and cancer stem cell marker CD133 in ovarian cancers.

Authors:  Yong-Il Ji; Bo-Young Lee; Yun-Jeong Kang; Jin-Ok Jo; Sang Ho Lee; Heung Yeol Kim; Young-Ok Kim; Chulmin Lee; Suk Bong Koh; Ari Kim; Ji Young Lee; Min Hyung Jung; Mee Sun Ock; Hee-Jae Cha
Journal:  Pathol Oncol Res       Date:  2012-10-10       Impact factor: 3.201

5.  Possible functional involvement of thymosin beta 4 in developing tooth germ of mouse lower first molar.

Authors:  Merina Akhter; Ieyoshi Kobayashi; Tamotsu Kiyoshima; Kou Matsuo; Haruyoshi Yamaza; Hiroko Wada; Jun-ya Honda; Xie Ming; Hidetaka Sakai
Journal:  Histochem Cell Biol       Date:  2005-10-28       Impact factor: 4.304

6.  Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma.

Authors:  Belamy B Cheung; Owen Tan; Jessica Koach; Bing Liu; Michael S Y Shum; Daniel R Carter; Selina Sutton; Sela T Po'uha; Louis Chesler; Michelle Haber; Murray D Norris; Maria Kavallaris; Tao Liu; Geraldine M O'Neill; Glenn M Marshall
Journal:  Mol Oncol       Date:  2015-04-29       Impact factor: 6.603

Review 7.  Heme oxygenase-1 in tumors: is it a false friend?

Authors:  Alicja Jozkowicz; Halina Was; Jozef Dulak
Journal:  Antioxid Redox Signal       Date:  2007-12       Impact factor: 8.401

8.  Thymosin β4 has tumor suppressive effects and its decreased expression results in poor prognosis and decreased survival in multiple myeloma.

Authors:  Jo Caers; Dirk Hose; Ine Kuipers; Tomas Jan Bos; Els Van Valckenborgh; Eline Menu; Elke De Bruyne; Hartmut Goldschmidt; Ben Van Camp; Bernard Klein; Karin Vanderkerken
Journal:  Haematologica       Date:  2009-10-14       Impact factor: 9.941

Review 9.  Biomarkers for predicting future metastasis of human gastrointestinal tumors.

Authors:  Lui Ng; Ronnie Tung Ping Poon; Roberta Pang
Journal:  Cell Mol Life Sci       Date:  2013-01-31       Impact factor: 9.261

10.  Thymosin Beta 4 is overexpressed in human pancreatic cancer cells and stimulates proinflammatory cytokine secretion and JNK activation.

Authors:  Yuqing Zhang; Louis W Feurino; Qihui Zhai; Hao Wang; William E Fisher; Changyi Chen; Qizhi Yao; Min Li
Journal:  Cancer Biol Ther       Date:  2007-12-13       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.